Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma
Zengin Z, Chehrazi-Raffle A, Salgia N, Muddasani R, Ali S, Meza L, Pal S. Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma. Urologic Oncology Seminars And Original Investigations 2021, 40: 25-36. PMID: 34840077, DOI: 10.1016/j.urolonc.2021.10.003.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsUrothelial carcinomaCheckpoint inhibitorsTargeted therapyLower tract diseaseMultiple disease stagesMetastatic urothelial carcinomaOverall response rateAntibody-drug conjugatesGrowth factor receptor familyFGFR3 inhibitionUC tumorsChemotherapy regimensUpper tractOngoing trialsDisease stageTract diseaseTreatment paradigmFactor receptor familyHigh incidenceActionable mutationsFGFR1-4FGFR3 inhibitorsSmall molecule inhibitorsFGFR3 mutations